S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at bone marrow and blood samples from patients with leukemia or other hematopoietic cancers.
|Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms||Genetic: cytogenetic analysis Genetic: fluorescence in situ hybridization|
|Official Title:||S9007, Cytogenetic Studies in Leukemia Patients|
- Maintain and expand a database of cytogenetic information on leukemia patients. [ Time Frame: While protocol was open ]
Biospecimen Retention: None Retained
|Study Start Date:||July 1991|
|Study Completion Date:||January 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
* Maintain and expand a database of cytogenetic information on leukemia patients.
Other objectives as funding permits:
- Determine the frequency and prognostic significance of cytogenetic abnormalities in bone marrow or peripheral blood cells in patients with leukemia prior to treatment and at various times during treatment undergoing treatment on a companion clinical trial.
- Correlate the presence of cytogenetic features with clinical, pathophysiological, cellular, and molecular characteristics in these patients.
- Provide quality control for all Southwest Oncology Group cytogenetic data.
OUTLINE: Bone marrow and/or peripheral blood samples from patients on specific treatment protocols for leukemia are analyzed for cytogenetic abnormalities. Samples from patients with chronic lymphocytic leukemia (CLL) are analyzed for trisomy 12 by fluorescence in situ hybridization and conventional cytogenetics.
PROJECTED ACCRUAL: Approximately 2,500 patients (1,200 with first-line acute myeloid leukemia [AML], 500 with first-line acute lymphoblastic leukemia [ALL], 200 with relapsed AML, 125 with chronic phase chronic myelogenous leukemia [CML], 100 with accelerated phase or blastic phase CML, 250 with hairy cell leukemia, and 125 with relapsed ALL or CLL) will be accrued for this study within 5 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00996047
Show 280 Study Locations
|Study Chair:||Elisabeth Paietta, PhD||Our Lady of Mercy Medical Center|